Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > duration

: 12-24 hours

or 4 hours (IR); 12 hours (ER)

or Hours

Use the filters below to narrow your results.

Ascorbic acid (vitamin C) (1) · Bisacodyl (1) · Budesonide (1) · Cefdinir (1) · Celecoxib (1) · Docusate (sodium or calcium) (1) · Enalapril (and enalaprilat IV) (1) · Fexofenadine (1) · Guaifenesin (1) · Lactulose (1) · Polyethylene glycol 3350 (PEG 3350) (1)

Allegra, Allegra Allergy 24 Hour, Mucinex Allergy (combo) — all now OTC in US (1) · Celebrex (oral capsules), Elyxyb (oral solution, for acute migraine) (1) · Colace (sodium), Surfak (calcium); many generics OTC (1) · Dulcolax, Correctol, Bisac-Evac (1) · Generic; huge OTC presence (1) · Kristalose, Constulose, Generlac, Enulose (1) · MiraLAX (OTC), GlycoLax, GoLYTELY (with electrolytes for bowel prep), CoLyte, MoviPrep, NuLYTELY (1) · Mucinex, Robitussin, Tussin (1) · Omnicef (discontinued in US under brand); mostly generic (1) · Pulmicort (inhaled), Rhinocort (intranasal), Entocort EC and Uceris (enteric-coated oral for IBD), Symbicort (with formoterol) (1) · Vasotec, Vasotec IV, Epaned (1)

None (7) · '"`UNIQ--vote-00000CC9-QINU`"' Mostly excreted unchanged in feces and urine; P-glycoprotein substrate (the basis of the fruit-juice interaction). (1) · '"`UNIQ--vote-0000104D-QINU`"' Adequate hydration is at least as important as the drug in producing the expectorant effect clinically. Used in combination with dextromethorphan, decongestants, or antihistamines in many proprietary OTC cold preparations. (1) · '"`UNIQ--vote-00001067-QINU`"' Chronic use is associated with cathartic colon (colonic dilation, loss of haustration), hypokalemia, and laxative dependence; reserved for short-term use or bowel prep with breaks between courses'"`UNIQ--ref-00001068-QINU`"'. (1) · '"`UNIQ--vote-0000132D-QINU`"' Electrolyte-balanced bowel-prep formulations are designed to be iso-osmotic with plasma so the volume passes through without net fluid or electrolyte shifts, the basis of their safety for whole-bowel evacuation. (1)

100-200 mg PO once or twice daily; pediatric weight-based (1) · 200-400 mg PO q4h (IR); 600-1200 mg PO q12h (Mucinex 12-Hour ER) (1) · 300 mg PO BID, or 600 mg PO once daily, ×5-10 days; pediatric 14 mg/kg/d (1) · 5-10 mg PO once daily (2.5 mg if on diuretic or in heart failure); titrate to 10-20 mg BID for HFrEF (1) · 5-15 mg PO once at bedtime; 10 mg PR for faster effect; bowel prep regimens use higher single doses (1) · 60 mg PO BID or 180 mg PO once daily (1) · Constipation: 15-30 mL PO daily (titrate to 1-2 soft stools/day); hepatic encephalopathy: 20-30 g (30-45 mL) PO/PR every 1-2 hours acutely until soft stools, then BID-QID to target 2-3 soft stools/day (1) · Constipation: 17 g (one capful) PO daily dissolved in 4-8 oz fluid; bowel prep: 4 L of PEG-electrolyte solution split-dose evening before and morning of procedure (1) · General supplementation 75-90 mg/d (RDA); scurvy treatment 100-1000 mg/d for several weeks; megadose claims unsupported (1) · ICS Pulmicort Flexhaler 180-360 mcg BID; intranasal Rhinocort 64 mcg/spray, 1-2 sprays/nostril daily; Entocort EC 9 mg PO daily for active Crohn's; Symbicort 80/4.5 or 160/4.5 mcg, 2 puffs BID (1) · Osteoarthritis: 200 mg PO once daily or 100 mg BID. Rheumatoid arthritis: 100-200 mg PO BID. Acute pain: 400 mg loading, then 200 mg every 12 hours (1)

10 g/15 mL solution (Constulose); 10 g, 20 g powder packets (Kristalose) (1) · 100, 200, 400 mg IR tablets; 600 mg, 1200 mg Mucinex ER tablets; many liquid formulations and combination products with dextromethorphan, pseudoephedrine, antihistamines (1) · 100, 250, 500, 1000 mg tablets, chewables, gummies, effervescent; IV (specialty) (1) · 17 g (OTC) and 14 g (Rx) powder packets; 238, 510, 527 g bottles; PEG-electrolyte preparations 4 L (GoLYTELY, NuLYTELY) (1) · 2.5, 5, 10, 20 mg tablets; 1 mg/mL oral solution (Epaned); 1.25 mg/mL IV (enalaprilat) (1) · 30, 60, 180 mg tablets; 30 mg ODT; 6 mg/mL oral suspension; all OTC (1) · 300 mg capsules; 125, 250 mg/5 mL suspension (1) · 5 mg enteric-coated tablets; 10 mg rectal suppositories; OTC and Rx (1) · 50, 100, 250 mg capsules; 50 mg/5 mL syrup; OTC (1) · Capsules 50, 100, 200, 400 mg; Elyxyb oral solution 25 mg/mL (1) · Pulmicort Flexhaler DPI 90, 180 mcg/dose; Pulmicort Respules 0.25, 0.5, 1 mg/2 mL nebulized; Rhinocort intranasal 32 mcg/spray; Entocort EC 3 mg capsules; Uceris 9 mg ER tablets and rectal foam (1)

180 mg/d (adults) (1) · 2.4 g/d (1) · 30 mg/d for short-term use (1) · 40 mg/d (1) · 400 mg/day for chronic indications; higher for short-term acute pain (1) · 600 mg/d (1) · ICS ~1280 mcg/d; intranasal 256 mcg/d; Entocort 9 mg/d standard (1) · Indication-specific; bowel prep regimens reach 4 L cumulative (1) · Indication-specific; HE may require high-volume dosing (1) · UL 2000 mg/d in adults (1) · ~500 mg/d typical (1)

especially in acute HE) (1) · Inhaled (1) · intranasal (1) · IV (2) · nebulized (1) · Oral (10) · oral (enteric-coated (1) · rectal (2) · rectal (enema (1) · rectal foam) (1)

1-2 hours (1) · 1-3 days (1) · 30 minutes (1) · 30-60 minutes (1) · BP effect 1 hour; max at 4-6 hours (1) · Constipation: 1-3 days; bowel prep: 1-3 hours after starting (1) · Constipation: 24-48 hours; HE: ammonia reduction within hours of stool production (1) · Days for symptom improvement in scurvy (1) · Hours (1) · Inhaled: bronchial effect 1-2 weeks; oral GI effect 1-2 weeks (1) · PO 6-12 hours; PR 15-60 minutes (1)

Not meaningfully described (1) · Not meaningfully described (negligible systemic absorption) (1) · Not meaningfully described — lactulose is not significantly absorbed (1) · Variable; effect dependent on local intestinal action rather than systemic kinetics'"`UNIQ--ref-0000106B-QINU`"' (1) · ~1 hour'"`UNIQ--ref-00001050-QINU`"' (1) · ~1.7 hours'"`UNIQ--ref-000009E4-QINU`"' (1) · ~10-20 days (steady-state body pool); single dose plasma ~2 hours (1) · ~11 hours (enalaprilat, the active metabolite)'"`UNIQ--ref-00000B84-QINU`"' (1) · ~11 hours'"`UNIQ--ref-00000029-QINU`"' (1) · ~14 hours'"`UNIQ--ref-00000CCC-QINU`"' (1) · ~2-3.6 hours (plasma)'"`UNIQ--ref-000009A5-QINU`"' (1)

16-21% capsule, 25% suspension (oral; iron and antacids reduce absorption substantially)'"`UNIQ--ref-000009E5-QINU`"' (1) · <0.1% systemic absorption (PEG 3350 is too large to absorb intact) (1) · <3% systemic absorption (the basis of the safety and mechanism)'"`UNIQ--ref-00000F5E-QINU`"' (1) · High (oral)'"`UNIQ--ref-00001051-QINU`"' (1) · Local action; minimal systemic effect (1) · Low systemic absorption (enteric coating delivers drug to colon)'"`UNIQ--ref-0000106C-QINU`"' (1) · ~33% (oral; fruit juices including grapefruit, orange, and apple reduce absorption substantially via OATP1A2 inhibition — distinctive interaction not seen with most other H1s)'"`UNIQ--ref-00000CCD-QINU`"' (1) · ~6-13% inhaled lung deposition; ~10% oral (Entocort EC; extensive first-pass via CYP3A4 — this is the basis of the favorable hepatic-targeted local-effect profile in IBD)'"`UNIQ--ref-000009A6-QINU`"' (1) · ~60% (oral; food does not affect absorption)'"`UNIQ--ref-00000B85-QINU`"' (1) · ~70-90% at typical doses; saturable at high doses (>500 mg) (1) · ~99% (oral)'"`UNIQ--ref-0000002A-QINU`"' (1)

'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-00000B86-QINU`"' (1) · Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-0000002B-QINU`"' (1) · Generally considered acceptable for short-term use.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered acceptable.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe (minimal systemic absorption).[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe due to minimal systemic absorption.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe in pregnancy.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe; loratadine and cetirizine have more pregnancy data and are typically preferred.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Long the preferred ICS in pregnancy (Pulmicort) due to the most pregnancy data among the class.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Safe at routine doses; routinely supplemented in pregnancy.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

OTC (intranasal Rhinocort Allergy) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) · OTC (MiraLAX) and [[USLegal:Prescription only|Rx-only]] (electrolyte solutions for bowel prep) in US (1) · OTC in US (5) · [[USLegal:Prescription only|Rx-only]] in US (4)

Showing below up to 11 results in range #1 to #11.

A

Ascorbic Acid

B